Research programme: ophthalmologic gene therapy - Adverum/Regeneron

Drug Profile

Research programme: ophthalmologic gene therapy - Adverum/Regeneron

Alternative Names: AVA 311

Latest Information Update: 08 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avalanche Biotechnologies; Regeneron Pharmaceuticals
  • Developer Adverum Biotechnologies; Regeneron Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Retinoschisis

Most Recent Events

  • 07 Mar 2017 Regeneron extends the license agreement with Adverum for additional three years
  • 24 Nov 2015 CRISPR-Cas9 genome-editing patents licensed to Regeneron Pharmaceuticals
  • 24 Nov 2015 ERS Genomics has patent protection for CRISPR-Cas9 patent portfolio in US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top